<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Garcia-Montojo M</submitter><funding>ALS Association</funding><pagination>782-792</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9805205</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>92(5)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Reactivation of HERV-K(HML-2) has been found in subsets of individuals with amyotrophic lateral sclerosis (ALS). This study examines the antibody response against HML-2 in ALS and analyzes its clinical relevance.&lt;h4>Methods&lt;/h4>Antibodies to HML-2 envelope (env) were analyzed using a peptide array for epitope mapping and by a peptide enzyme-linked immunosorbent assay (ELISA) in 242 healthy donors, and 243 ALS and 85 multiple sclerosis (MS) individuals. Extracellular levels of HML-2 were analyzed by digital polymerase chain reaction (PCR).&lt;h4>Results&lt;/h4>Antibodies in the sera of ALS individuals recognized more HML-2 env peptides compared to healthy controls (p &lt; 0.0001). ALS individuals had higher levels of HML-2 than healthy donors (p = 0.02) and higher antibody levels </pubmed_abstract><journal>Annals of neurology</journal><pubmed_title>Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.</pubmed_title><pmcid>PMC9805205</pmcid><funding_grant_id>20‐SI‐559</funding_grant_id><pubmed_authors>Fathi S</pubmed_authors><pubmed_authors>Simula ER</pubmed_authors><pubmed_authors>Johnson K</pubmed_authors><pubmed_authors>Berry JD</pubmed_authors><pubmed_authors>Nath A</pubmed_authors><pubmed_authors>Cudkowicz M</pubmed_authors><pubmed_authors>Sechi LA</pubmed_authors><pubmed_authors>Garcia-Montojo M</pubmed_authors><pubmed_authors>Ghosal A</pubmed_authors><pubmed_authors>Norato G</pubmed_authors><pubmed_authors>McMahan C</pubmed_authors><pubmed_authors>Elkahloun A</pubmed_authors><pubmed_authors>James T</pubmed_authors><pubmed_authors>Jensen P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.</name><description>&lt;h4>Objectives&lt;/h4>Reactivation of HERV-K(HML-2) has been found in subsets of individuals with amyotrophic lateral sclerosis (ALS). This study examines the antibody response against HML-2 in ALS and analyzes its clinical relevance.&lt;h4>Methods&lt;/h4>Antibodies to HML-2 envelope (env) were analyzed using a peptide array for epitope mapping and by a peptide enzyme-linked immunosorbent assay (ELISA) in 242 healthy donors, and 243 ALS and 85 multiple sclerosis (MS) individuals. Extracellular levels of HML-2 were analyzed by digital polymerase chain reaction (PCR).&lt;h4>Results&lt;/h4>Antibodies in the sera of ALS individuals recognized more HML-2 env peptides compared to healthy controls (p &lt; 0.0001). ALS individuals had higher levels of HML-2 than healthy donors (p = 0.02) and higher antibody levels </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-05-28T03:54:40.584Z</modification><creation>2025-02-19T02:37:49.809Z</creation></dates><accession>S-EPMC9805205</accession><cross_references><pubmed>36053951</pubmed><doi>10.1002/ana.26466</doi></cross_references></HashMap>